T1	PROC 54 86	Estudio aleatorizado de fase III
T2	PROC 96 147	trasplante de células hematopoyéticas haploidéntico
#1	AnnotatorNotes T2	C4527425; Haploidentical Hematopoietic Cell Transplantation; Therapeutic or Preventive Procedure
T3	ANAT 110 133	células hematopoyéticas
#2	AnnotatorNotes T3	C2323499; Hematopoietic cell; Cell
T4	PROC 204 211	donados
#3	AnnotatorNotes T4	C3489429; Embryo Donation; Health Care Activity
T5	DISO 230 244	leucemia aguda
#4	AnnotatorNotes T5	C0085669; Acute leukemia; Neoplastic Process
T6	PROC 310 327	HCT haploidéntico
T7	DISO 342 358	leucemias agudas
#5	AnnotatorNotes T7	C0085669; Acute leukemia; Neoplastic Process
T8	DISO 539 542	LMA
#6	AnnotatorNotes T8	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T9	DISO 545 548	LLA
#7	AnnotatorNotes T9	C0023449; Acute lymphocytic leukemia; Neoplastic Process
T10	DISO 658 661	LMA
#8	AnnotatorNotes T10	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T11	DISO 664 667	LLA
#9	AnnotatorNotes T11	C0023449; Acute lymphocytic leukemia; Neoplastic Process
T12	DISO 702 716	LMA secundaria
#10	AnnotatorNotes T12	C0280449; Secondary Acute Myeloid Leukemia; Neoplastic Process
T13	PROC 774 777	HLA
#11	AnnotatorNotes T13	C2348930; HLA Compatibility Testing; Laboratory Procedure
T14	PROC 944 968	consentimiento informado
#12	AnnotatorNotes T14	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T15	PROC 1019 1043	estudio de investigación
#13	AnnotatorNotes T15	C0681814; research study; Research Activity
T16	DISO 1109 1136	reacciones adversas tóxicas
T17	DISO 1183 1193	enfermedad
#14	AnnotatorNotes T17	C0012634; Disease; Disease or Syndrome
T18	DISO 1196 1208	complicación
#15	AnnotatorNotes T18	C0009566; Complication; Pathologic Function
T19	DISO 1247 1257	enfermedad
#16	AnnotatorNotes T19	C0012634; Disease; Disease or Syndrome
T20	PROC 1291 1342	trasplante de células hematopoyéticas haploidéntico
#17	AnnotatorNotes T20	C4527425; Haploidentical Hematopoietic Cell Transplantation; Therapeutic or Preventive Procedure
T21	ANAT 1305 1328	células hematopoyéticas
#18	AnnotatorNotes T21	C2323499; Hematopoietic cell; Cell
T22	DISO 1388 1413	enfermedad activa del SNC
T23	ANAT 1410 1413	SNC
#19	AnnotatorNotes T23	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T24	PROC 1550 1575	esterilización quirúrgica
T25	PROC 1592 1615	métodos anticonceptivos
#20	AnnotatorNotes T25	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T26	PROC 1702 1720	prueba de embarazo
#21	AnnotatorNotes T26	C0032976; Pregnancy Tests; Diagnostic Procedure
T27	ANAT 1725 1730	suero
#22	AnnotatorNotes T27	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T28	DISO 1844 1855	Infecciones
#23	AnnotatorNotes T28	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T29	CHEM 1891 1902	ganciclovir
#24	AnnotatorNotes T29	C0017066; ganciclovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T30	CHEM 1904 1918	valganciclovir
#25	AnnotatorNotes T30	C0909381; valganciclovir; Organic Chemical · Pharmacologic Substance
T31	CHEM 1921 1930	aciclovir
#26	AnnotatorNotes T31	C0001367; acyclovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T32	ANAT 1965 1982	linfocitos HSV-TK
#27	AnnotatorNotes T32	C1881029; HSV-TK-Transduced Donor Lymphocytes; Cell
T33	PROC 2028 2064	suspensión del tratamiento antiviral
T34	PROC 2086 2122	tratamiento inmunosupresor sistémico
T35	PROC 2126 2162	Tratamiento inmunosupresor sistémico
T36	PROC 2183 2234	trasplante de células hematopoyéticas haploidéntico
#28	AnnotatorNotes T36	C4527425; Haploidentical Hematopoietic Cell Transplantation; Therapeutic or Preventive Procedure
T37	ANAT 2197 2220	células hematopoyéticas
#29	AnnotatorNotes T37	C2323499; Hematopoietic cell; Cell
T38	CHEM 2263 2309	factor estimulante de colonias de granulocitos
#30	AnnotatorNotes T38	C0079459; Granulocyte Colony-Stimulating Factor; Amino Acid, Peptide, or Protein · Immunologic Factor
T39	ANAT 2297 2309	granulocitos
#31	AnnotatorNotes T39	C0018183; granulocyte; Cell
T40	PROC 2322 2373	trasplante de células hematopoyéticas haploidéntico
#32	AnnotatorNotes T40	C4527425; Haploidentical Hematopoietic Cell Transplantation; Therapeutic or Preventive Procedure
T41	ANAT 2336 2359	células hematopoyéticas
#33	AnnotatorNotes T41	C2323499; Hematopoietic cell; Cell
T42	PROC 2377 2392	Linfocitos CD3+
T43	PROC 2457 2508	trasplante de células hematopoyéticas haploidéntico
#34	AnnotatorNotes T43	C4527425; Haploidentical Hematopoietic Cell Transplantation; Therapeutic or Preventive Procedure
T44	ANAT 2471 2494	células hematopoyéticas
#35	AnnotatorNotes T44	C2323499; Hematopoietic cell; Cell
T45	ANAT 186 203	linfocitos HSV-TK
#36	AnnotatorNotes T45	C1881029; HSV-TK-Transduced Donor Lymphocytes; Cell
T46	DISO 2068 2072	EICH
#37	AnnotatorNotes T46	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T47	PHYS 1508 1520	menopáusicas
#38	AnnotatorNotes T47	C0206159; Postmenopause; Organism Function
T48	ANAT 1832 1838	HSV-Tk
T49	ANAT 1733 1738	orina
#39	AnnotatorNotes T49	C0042036; Urine; Body Substance
T50	PROC 1820 1828	infusión
#40	AnnotatorNotes T50	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T51	PROC 1873 1887	administración
#41	AnnotatorNotes T51	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T52	PROC 1951 1959	infusión
#42	AnnotatorNotes T52	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T53	CHEM 2055 2064	antiviral
#43	AnnotatorNotes T53	C0003451; Antiviral Agents; Pharmacologic Substance
T54	CHEM 2098 2112	inmunosupresor
#44	AnnotatorNotes T54	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T55	CHEM 2138 2152	inmunosupresor
#45	AnnotatorNotes T55	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T56	PROC 2238 2252	Administración
#46	AnnotatorNotes T56	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T57	CHEM 2256 2261	G-CSF
#47	AnnotatorNotes T57	C0079459; Granulocyte Colony-Stimulating Factor; Amino Acid, Peptide, or Protein · Immunologic Factor | C0210630; filgrastim; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T58	PROC 2415 2423	infusión
#48	AnnotatorNotes T58	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T59	Date 12 16	2009
T60	Neg_cue 154 157	sin
T62	LIVB 216 225	pacientes
#49	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	LIVB 289 298	pacientes
#50	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T65	Age 483 492	≥ 18 años
T68	Neg_cue 725 736	Ausencia de
T69	LIVB 737 786	donante emparentado o no emparentado HLA idéntico
#51	AnnotatorNotes T69	C4330663; Matched Related Donor; Population Group + C4318937; Matched Unrelated Donor; Population Group
T71	Duration 839 848	> 3 meses
T72	LIVB 883 892	pacientes
#52	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	LIVB 919 927	donantes
#53	AnnotatorNotes T73	C2191327; donor of organ or tissue; Patient or Disabled Group
T74	Spec_cue 1077 1085	posibles
T75	LIVB 1165 1174	Pacientes
#54	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T76	Spec_cue 1209 1223	potencialmente
T77	DISO 1224 1230	mortal
#55	AnnotatorNotes T77	C1306577; Death (finding); Finding | C1546956; Patient Outcome - Died; Finding
T78	LIVB 1359 1371	Investigador
#56	AnnotatorNotes T78	C0035173; Research Personnel; Professional or Occupational Group
T79	LIVB 1374 1383	Pacientes
#57	AnnotatorNotes T79	C0030705; Patients; Patient or Disabled Group
T80	PHYS 1416 1424	Embarazo
#58	AnnotatorNotes T80	C0032961; Pregnancy; Organism Function
T81	PHYS 1427 1436	lactancia
#59	AnnotatorNotes T81	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T82	LIVB 1442 1469	pacientes varones y mujeres
#60	AnnotatorNotes T82	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T84	PHYS 1474 1496	capacidad reproductora
#61	AnnotatorNotes T84	C0232896; Reproductive function; Physiologic Function
T86	Duration 1529 1543	menos de 1 año
T87	Neg_cue 1546 1549	sin
T88	LIVB 1653 1675	mujeres en edad fértil
#62	AnnotatorNotes T88	C4324275; Woman of childbearing potential; Population Group
T89	Age 1664 1675	edad fértil
T91	Neg_cue 1686 1694	negativo
T93	Duration 1753 1764	los 14 días
T99	Duration 2005 2013	24 horas
T101	Date 2163 2171	en curso
T103	PHYS 118 133	hematopoyéticas
#63	AnnotatorNotes T103	C0018951; Hematopoiesis; Organ or Tissue Function
T104	PHYS 1313 1328	hematopoyéticas
#64	AnnotatorNotes T104	C0018951; Hematopoiesis; Organ or Tissue Function
T105	PHYS 1712 1720	embarazo
#65	AnnotatorNotes T105	C0032961; Pregnancy; Organism Function
T106	PHYS 2205 2220	hematopoyéticas
#66	AnnotatorNotes T106	C0018951; Hematopoiesis; Organ or Tissue Function
T107	PHYS 2344 2359	hematopoyéticas
#67	AnnotatorNotes T107	C0018951; Hematopoiesis; Organ or Tissue Function
T108	PHYS 2479 2494	hematopoyéticas
#68	AnnotatorNotes T108	C0018951; Hematopoiesis; Organ or Tissue Function
T61	LIVB 896 911	tutores legales
#69	AnnotatorNotes T61	C0023226; Legal Guardians; Population Group
T64	Spec_cue 587 593	riesgo
T66	DISO 602 610	recidiva
#70	AnnotatorNotes T66	C0699753; Cancer Relapse; Neoplastic Process
T67	Spec_cue 432 441	riesgo de
T70	DISO 442 449	recaída
#71	AnnotatorNotes T70	C0699753; Cancer Relapse; Neoplastic Process
T85	PROC 849 851	EF
#72	AnnotatorNotes T85	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
A1	Assertion T45 Negated
A2	Assertion T4 Negated
A3	Assertion T69 Negated
A4	Assertion T16 Speculated
A5	Assertion T77 Negated
A6	Assertion T24 Negated
A7	Assertion T105 Negated
A8	Assertion T66 Speculated
A9	Assertion T70 Speculated
A10	Assertion T20 Contraindicated
#73	AnnotatorNotes T1	C0034656; Randomization; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity
#74	AnnotatorNotes T6	C4527425; Haploidentical Hematopoietic Cell Transplantation; Therapeutic or Preventive Procedure
#75	AnnotatorNotes T16	C0542243; Toxic reaction (NOS); Finding
#76	AnnotatorNotes T48	C1881029; HSV-TK-Transduced Donor Lymphocytes; Cell
T83	Quantifier_or_Qualifier 762 773	emparentado
A11	Assertion T83 Negated
T90	Neg_cue 759 761	no
T92	Quantifier_or_Qualifier 745 756	emparentado
R1	Negation Arg1:T60 Arg2:T45	
R2	Negation Arg1:T60 Arg2:T4	
R3	Speculation Arg1:T67 Arg2:T70	
R4	Speculation Arg1:T64 Arg2:T66	
R5	Negation Arg1:T68 Arg2:T69	
R6	Negation Arg1:T90 Arg2:T83	
R7	Has_Quantifier_or_Qualifier Arg1:T69 Arg2:T83	
R8	Has_Quantifier_or_Qualifier Arg1:T69 Arg2:T92	
R9	Speculation Arg1:T74 Arg2:T16	
T94	Observation 1086 1106	efectos beneficiosos
A12	Assertion T94 Speculated
#77	AnnotatorNotes T94	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R10	Speculation Arg1:T74 Arg2:T94	
R11	Speculation Arg1:T76 Arg2:T77	
R12	Negation Arg1:T87 Arg2:T24	
R13	Negation Arg1:T91 Arg2:T105	
R15	Combined_with Arg1:T2 Arg2:T4	
R16	Experiences Arg1:T62 Arg2:T2	
R17	Experiences Arg1:T62 Arg2:T5	
T95	Observation 248 259	alto riesgo
#78	AnnotatorNotes T95	C4319571; High risk; Finding
R18	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T95	
T96	Observation 427 441	alto riesgo de
#79	AnnotatorNotes T96	C0332167; High risk of; Finding
R19	Before Arg1:T96 Arg2:T70	
T97	Observation 587 601	riesgo alto de
#80	AnnotatorNotes T97	C0332167; High risk of; Finding
R20	Before Arg1:T97 Arg2:T66	
R21	Experiences Arg1:T63 Arg2:T6	
R22	Experiences Arg1:T63 Arg2:T7	
T98	Quantifier_or_Qualifier 362 369	primera
#81	AnnotatorNotes T98	C0205435; First (number); Quantitative Concept
T100	Quantifier_or_Qualifier 552 559	primera
#82	AnnotatorNotes T100	C0205435; First (number); Quantitative Concept
T102	Observation 560 577	remisión completa
#83	AnnotatorNotes T102	C0677874; In complete remission; Finding
R23	Has_Quantifier_or_Qualifier Arg1:T102 Arg2:T100	
R24	Overlap Arg1:T8 Arg2:T102	
R25	Overlap Arg1:T9 Arg2:T102	
T109	Observation 370 387	remisión completa
#84	AnnotatorNotes T109	C0677874; In complete remission; Finding
R26	Overlap Arg1:T7 Arg2:T109	
R27	Has_Quantifier_or_Qualifier Arg1:T109 Arg2:T98	
T110	Observation 390 407	remisión completa
#85	AnnotatorNotes T110	C0677874; In complete remission; Finding
T111	Quantifier_or_Qualifier 408 420	subsiguiente
R28	Has_Quantifier_or_Qualifier Arg1:T110 Arg2:T111	
R29	Experiences Arg1:T63 Arg2:T109	
R30	Experiences Arg1:T63 Arg2:T110	
R31	Experiences Arg1:T63 Arg2:T96	
R32	Before Arg1:T7 Arg2:T70	
R33	Overlap Arg1:T8 Arg2:T97	
R34	Overlap Arg1:T9 Arg2:T97	
R35	Before Arg1:T8 Arg2:T66	
R36	Before Arg1:T9 Arg2:T66	
R37	Overlap Arg1:T7 Arg2:T96	
T112	Observation 579 581	RC
#86	AnnotatorNotes T112	C0677874; In complete remission; Finding
R38	Has_Quantifier_or_Qualifier Arg1:T112 Arg2:T100	
R39	Overlap Arg1:T8 Arg2:T112	
R40	Overlap Arg1:T9 Arg2:T112	
T113	CONC 868 872	ECOG
#87	AnnotatorNotes T113	C1520224; ECOG performance status; Intellectual Product
T114	Result_or_Value 873 876	≤ 2
R41	Has_Result_or_Value Arg1:T113 Arg2:T114	
R42	Used_for Arg1:T113 Arg2:T85	
T115	Observation 1060 1069	informado
#88	AnnotatorNotes T115	C0587903; Patient information status; Finding (?)
R43	Before Arg1:T115 Arg2:T94	
R44	Before Arg1:T115 Arg2:T14	
R46	Experiences Arg1:T72 Arg2:T94	
R47	Experiences Arg1:T72 Arg2:T16	
R48	Before Arg1:T115 Arg2:T16	
R49	Before Arg1:T14 Arg2:T94	
R50	Before Arg1:T14 Arg2:T15	
R51	Before Arg1:T14 Arg2:T16	
R52	Experiences Arg1:T75 Arg2:T17	
R53	Experiences Arg1:T75 Arg2:T18	
R54	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T77	
R55	Experiences Arg1:T75 Arg2:T77	
R56	Experiences Arg1:T75 Arg2:T19	
T116	Observation 626 655	factores pronóstico negativos
#89	AnnotatorNotes T116	C0278252; Prognosis bad; Finding
R58	Before Arg1:T116 Arg2:T66	
T117	Observation 679 681	RC
#90	AnnotatorNotes T117	C0677874; In complete remission; Finding
T118	Observation 684 686	RC
#91	AnnotatorNotes T118	C0677874; In complete remission; Finding
R59	Overlap Arg1:T10 Arg2:T117	
R60	Overlap Arg1:T10 Arg2:T118	
R61	Overlap Arg1:T11 Arg2:T117	
R62	Overlap Arg1:T11 Arg2:T118	
T119	Observation 720 722	RC
#92	AnnotatorNotes T119	C0677874; In complete remission; Finding
R63	Overlap Arg1:T12 Arg2:T119	
T120	Quantifier_or_Qualifier 671 678	segunda
T121	Quantifier_or_Qualifier 687 699	subsiguiente
#93	AnnotatorNotes T121	C0332282; Following; Temporal Concept
R64	Has_Quantifier_or_Qualifier Arg1:T118 Arg2:T121	
#94	AnnotatorNotes T111	C0332282; Following; Temporal Concept
R65	Has_Quantifier_or_Qualifier Arg1:T117 Arg2:T120	
T122	Observation 789 818	Condiciones clínicas estables
#95	AnnotatorNotes T122	C1282982; Patient's conditionstable; Finding
T123	CONC 821 838	esperanza de vida
#96	AnnotatorNotes T123	C0023671; Life Expectancy; Group Attribute
R66	Has_Duration_or_Interval Arg1:T123 Arg2:T71	
#97	AnnotatorNotes T120	C0205436; second (number); Quantitative Concept
R67	Experiences Arg1:T79 Arg2:T22	
R68	Location_of Arg1:T23 Arg2:T22	
#98	AnnotatorNotes T22	C0007682; CNS disorder; Disease or Syndrome (?)
R69	Experiences Arg1:T82 Arg2:T84	
R70	Has_Duration_or_Interval Arg1:T47 Arg2:T86	
R71	Overlap Arg1:T47 Arg2:T24	
R72	Experiences Arg1:T82 Arg2:T25	
R73	Overlap Arg1:T84 Arg2:T25	
R74	Overlap Arg1:T47 Arg2:T25	
R75	Has_Age Arg1:T88 Arg2:T89	
R76	Experiences Arg1:T88 Arg2:T26	
R77	Experiences Arg1:T88 Arg2:T105	
R78	Location_of Arg1:T27 Arg2:T26	
R79	Location_of Arg1:T49 Arg2:T26	
R80	Overlap Arg1:T26 Arg2:T93	
T124	Quantifier_or_Qualifier 1616 1624	eficaces
#99	AnnotatorNotes T124	C1704419; Effective; Qualitative Concept
R81	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T124	
T125	PROC 1641 1648	estudio
#100	AnnotatorNotes T125	C0008976; Clinical Trials; Research Activity
R82	Overlap Arg1:T25 Arg2:T125	
R83	Overlap Arg1:T84 Arg2:T125	
R84	Overlap Arg1:T47 Arg2:T125	
T126	PROC 1778 1786	registro
#101	AnnotatorNotes T126	C4041024; Enrollment in clinical trial; Research Activity
R85	Before Arg1:T26 Arg2:T126	
R86	Used_for Arg1:T29 Arg2:T51	
R87	Used_for Arg1:T30 Arg2:T51	
R88	Used_for Arg1:T31 Arg2:T51	
R89	Overlap Arg1:T51 Arg2:T52	
R91	Used_for Arg1:T53 Arg2:T33	
R92	After Arg1:T32 Arg2:T99	
R93	After Arg1:T32 Arg2:T33	
R94	Used_for Arg1:T54 Arg2:T34	
R95	Used_for Arg1:T55 Arg2:T35	
R96	Overlap Arg1:T35 Arg2:T101	
R97	After Arg1:T35 Arg2:T36	
R99	Used_for Arg1:T57 Arg2:T56	
R100	Used_for Arg1:T38 Arg2:T56	
R101	After Arg1:T56 Arg2:T40	
T127	Result_or_Value 2393 2401	≥ 100/µl
#102	AnnotatorNotes T42	C4481285; CD3+ cells in blood; Laboratory Procedure
R103	Has_Result_or_Value Arg1:T42 Arg2:T127	
R104	Overlap Arg1:T42 Arg2:T58	
R105	After Arg1:T58 Arg2:T43	
T128	Quantifier_or_Qualifier 2437 2445	prevista
#103	AnnotatorNotes T128	C1301732; Planned; Functional Concept
R107	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T128	
R108	Experiences Arg1:T62 Arg2:T95	
R109	Experiences Arg1:T63 Arg2:T70	
R14	Overlap Arg1:T7 Arg2:T110	
R57	Experiences Arg1:T82 Arg2:T24	
R110	Used_for Arg1:T48 Arg2:T50	
#104	AnnotatorNotes T101	C0521116; Current (present time); Temporal Concept
#105	AnnotatorNotes T92	C0439849; Relationships; Qualitative Concept (?)
#106	AnnotatorNotes T83	C0439849; Relationships; Qualitative Concept (?)
A13	Experiencer T62 Patient
A14	Experiencer T63 Patient
A15	Experiencer T72 Patient
A16	Experiencer T73 Other
A17	Experiencer T61 Other
A18	Experiencer T75 Patient
A19	Experiencer T78 Other
A20	Experiencer T79 Patient
A21	Experiencer T82 Patient
A22	Experiencer T88 Patient
A23	Status T58 Future
A24	Experiencer T69 Other
T129	Result_or_Value 1686 1694	negativo
R45	Has_Result_or_Value Arg1:T26 Arg2:T129	
